Trial: 202111018

Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Phase

I

Principal Investigator

Ghobadi, Armin

Disease Site

Hodgkin Lymphoma; Leukemia, other; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin Lymphoma; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov